Oppenheimer analyst Owen Lau raised the firm’s price target on CME Group (CME) to $303 from $300 and keeps an Outperform rating on the shares. The firm notes CME delivered again another record quarter with revenue, ADV, adjusted operating income and adjusted EPS achieving all-time highs and were up double-digits year-over-year. Revenue was better than expected due to higher RPC, and expense guidance was dialed down due to lower spend on Google (GOOGL) migration and professional services. Given the positive results, the stock was up 0.7% vs. up 0.8% for S&P 500 at close, Oppenheimer adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- Positive Outlook for CME Group Driven by Risk Management Demand and Strong Financial Position
- CME Group price target lowered to $298 from $299 at Barclays
- CME Group Inc. Reports Record Q2 2025 Earnings
- CME Group reports Q2 adjusted EPS $2.96, consensus $2.92
- CME Group, Nasdaq announced ten-year extension of Nasdaq-100 futures license